AnaptysBio Non Current Liabilities Total vs Cash Analysis
| ANAB Stock | USD 25.07 0.40 1.57% |
AnaptysBio financial indicator trend analysis is way more than just evaluating AnaptysBio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AnaptysBio is a good investment. Please check the relationship between AnaptysBio Non Current Liabilities Total and its Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
Non Current Liabilities Total vs Cash
Non Current Liabilities Total vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AnaptysBio Non Current Liabilities Total account and Cash. At this time, the significance of the direction appears to have very week relationship.
The correlation between AnaptysBio's Non Current Liabilities Total and Cash is 0.24. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Cash in the same time period over historical financial statements of AnaptysBio, assuming nothing else is changed. The correlation between historical values of AnaptysBio's Non Current Liabilities Total and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of AnaptysBio are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Non Current Liabilities Total i.e., AnaptysBio's Non Current Liabilities Total and Cash go up and down completely randomly.
Correlation Coefficient | 0.24 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Non Current Liabilities Total
Cash
Cash refers to the most liquid asset of AnaptysBio, which is listed under current asset account on AnaptysBio balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from AnaptysBio customers. The amounts must be unrestricted with restricted cash listed in a different AnaptysBio account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from AnaptysBio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AnaptysBio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.At present, AnaptysBio's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.57, whereas Tax Provision is forecasted to decline to (4.2 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.5M | 21.1M | 18.1M | 19.0M | Depreciation And Amortization | 468K | 7.6M | 2.4M | 2.8M |
AnaptysBio fundamental ratios Correlations
Click cells to compare fundamentals
AnaptysBio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AnaptysBio fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
| Short Long Term Debt Total | 2.2M | 342K | 21.0M | 19.5M | 17.8M | 10.8M | |
| Other Current Liab | 871K | 15.3M | 12.9M | 21.6M | 31.0M | 32.5M | |
| Total Current Liabilities | 29.5M | 19.8M | 16.1M | 26.1M | 37.4M | 19.3M | |
| Total Stockholder Equity | 405.0M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
| Property Plant And Equipment Net | 1.6M | 1.8M | 21.8M | 20.0M | 18.3M | 19.2M | |
| Net Debt | (168.8M) | (250.1M) | (474.8M) | (51.9M) | (18.2M) | (19.1M) | |
| Retained Earnings | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (614.1M) | (583.4M) | |
| Accounts Payable | 16.2M | 4.2M | 1.7M | 2.8M | 4.7M | 4.2M | |
| Cash | 171.0M | 250.5M | 495.7M | 71.3M | 36.0M | 34.2M | |
| Non Current Assets Total | 57.5M | 20.0M | 89.2M | 163.2M | 45.6M | 53.5M | |
| Non Currrent Assets Other | 208K | 1.5M | 662K | 256K | 230.4K | 218.9K | |
| Cash And Short Term Investments | 374.2M | 393.7M | 548.1M | 441.2M | 390.9M | 295.2M | |
| Common Stock Shares Outstanding | 27.1M | 27.3M | 27.4M | 28.2M | 26.9M | 21.0M | |
| Liabilities And Stockholders Equity | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
| Non Current Liabilities Total | 654K | 4.6M | 270.5M | 322.2M | 326.8M | 343.2M | |
| Other Current Assets | 3.5M | 2.9M | 4.9M | 4.5M | 9.1M | 9.5M | |
| Other Stockholder Equity | 213.5M | 660.7M | 678.6M | 717.8M | 703.0M | 738.1M | |
| Total Liab | 30.2M | 19.8M | 286.6M | 348.3M | 364.3M | 382.5M | |
| Property Plant And Equipment Gross | 1.6M | 1.8M | 21.8M | 20.0M | 24.5M | 25.7M | |
| Total Current Assets | 377.7M | 396.6M | 553.9M | 447.2M | 406.8M | 300.8M | |
| Accumulated Other Comprehensive Income | 338K | (4K) | (422K) | (5.2M) | (797K) | (836.9K) | |
| Short Term Debt | 2.2M | 342K | 1.5M | 1.6M | 1.8M | 2.3M | |
| Other Liab | 796K | 654K | 251.1M | 304.4M | 350.1M | 367.6M | |
| Net Tangible Assets | 405.0M | 396.7M | 627.0M | 584.3M | 672.0M | 705.6M | |
| Other Assets | 208K | 139K | 18.2M | 256K | 294.4K | 279.7K | |
| Property Plant Equipment | 3.0M | 1.8M | 2.3M | 2.1M | 2.4M | 1.6M | |
| Capital Surpluse | 648.7M | 660.7M | 678.6M | 717.8M | 825.5M | 517.6M | |
| Retained Earnings Total Equity | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (405.4M) | (385.2M) | |
| Short Term Investments | 203.2M | 143.2M | 52.4M | 369.9M | 354.9M | 252.1M | |
| Capital Lease Obligations | 871K | 342K | 21.0M | 19.5M | 17.8M | 9.4M | |
| Net Invested Capital | 406.4M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
| Long Term Investments | 54.3M | 17.5M | 67.1M | 142.9M | 27.0M | 25.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.Note that the AnaptysBio information on this page should be used as a complementary analysis to other AnaptysBio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is AnaptysBio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.14) | Revenue Per Share 0.862 | Quarterly Revenue Growth 4.225 | Return On Assets (0.20) | Return On Equity (1.37) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.